Discovering, Developing And Delivering New Purification Strategies For Novel Therapy Development

While novel modalities such as cell and gene therapies present tremendous potential to mitigate and possibly cure diseases previously thought to be untreatable, current production approaches lead to unsustainable costs. This results in limited ability to produce medicines and get them to patients.

Notably, purification solutions that enabled engineered proteins and monoclonal antibodies (mAbs) have proven inefficient for downstream processing of next-generation biologics causing longer development and manufacturing timelines and higher costs. A commitment to innovation and collaboration across the industry is needed to expand these promising therapies beyond niche indications.

Working together, Astrea Bioseparations, Gamma Biosciences and Nanopareil are validating the nanofiber separation solutions for ion exchange chromatography of viruses, virus-like particles, AAV vectors and plasmid DNA compatible in both bind-and-elute and flow-through modes.